← Back to Search

Electrical Nerve Stimulation

Wearable Device for Electrical Nerve Stimulation for Atrial Fibrillation (STALL-AF Trial)

N/A
Recruiting
Led By Peng-Sheng Chen, MD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Symptomatic AF.
Symptomatic AF is defined by AF with patient-reported perception of one or more of the following symptoms: palpitations, dizziness/presyncope, syncope, dyspnea, chest pain, malaise, and fatigue and activity intolerance.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

STALL-AF Trial Summary

This trial will test if a wearable device that sends electrical signals to the body can help improve symptoms in people with atrial fibrillation by better controlling their heart rate.

Who is the study for?
This trial is for adults aged 18-75 with atrial fibrillation (AF) who've had at least one documented AF episode and are symptomatic, experiencing issues like palpitations or dizziness. They must have a left atrial size <50 mm and not responded to an antiarrhythmic drug. Exclusions include severe heart conditions, recent stroke or myocardial infarction, certain syndromes like Wolff Parkinson-White Syndrome, existing neuromodulation devices, allergies to ECG materials, pregnancy, congenital heart diseases, and active thyrotoxicosis.Check my eligibility
What is being tested?
The study tests if implanting a device that sends mild electrical signals under the skin can control heart rate in AF patients. Participants will either receive the device with active treatment or without (as a comparison group). The goal is to see if this intervention improves symptoms of AF compared to no electrical stimulation.See study design
What are the potential side effects?
While specific side effects aren't listed for this trial's interventions, potential risks may include discomfort at the implant site, infection risk from surgery for device placement and possible skin irritation from electrical stimulation.

STALL-AF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I experience symptoms from atrial fibrillation.
Select...
I experience symptoms like palpitations or dizziness due to my atrial fibrillation.
Select...
My condition did not improve after taking at least one heart rhythm medication.
Select...
My heart's left atrium is smaller than 50 mm.
Select...
I am between 18 and 75 years old.
Select...
I have had episodes of sudden irregular heartbeats that I could feel and have an ECG record of.
Select...
My condition did not improve after taking at least one medication for irregular heartbeat.
Select...
I have had atrial fibrillation lasting more than 30 seconds, confirmed by a week-long heart monitor test within the last 6 months.

STALL-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AF Burden
Secondary outcome measures
Ventricular Rate Control

STALL-AF Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental GroupExperimental Treatment1 Intervention
Will receive stimulation ScNS at 3.5mA output
Group II: Control GroupPlacebo Group1 Intervention
Does not receive therapy

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,700 Previous Clinical Trials
7,506,846 Total Patients Enrolled
9 Trials studying Atrial Fibrillation
1,222 Patients Enrolled for Atrial Fibrillation
Cedars-Sinai Medical CenterLead Sponsor
500 Previous Clinical Trials
164,833 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
400 Patients Enrolled for Atrial Fibrillation
Indiana UniversityOTHER
980 Previous Clinical Trials
983,246 Total Patients Enrolled
4 Trials studying Atrial Fibrillation
291 Patients Enrolled for Atrial Fibrillation

Media Library

Device Implant with Active Treatment (Electrical Nerve Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04529941 — N/A
Atrial Fibrillation Research Study Groups: Experimental Group, Control Group
Atrial Fibrillation Clinical Trial 2023: Device Implant with Active Treatment Highlights & Side Effects. Trial Name: NCT04529941 — N/A
Device Implant with Active Treatment (Electrical Nerve Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04529941 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any age restrictions for enrolment in this clinical trial?

"According to the rules for inclusion, participants must have attained 18 years of age and be under 75."

Answered by AI

How many participants are taking part in this clinical trial?

"Affirmative. Clinicaltrials.gov data confirms that this research is currently recruiting individuals, having first been posted on November 24 2021 and last edited on November 16 2022. This trial seeks to enrol 30 patients from a single location."

Answered by AI

May I submit my name to be considered for this research endeavor?

"This medical study is currently looking for 30 patients with a diagnosis of atrial fibrillation, aged 18 to 75 years. All applicants must meet the following criteria: between 18 and 75; reporting symptoms such as palpitations, dizziness/presyncope, syncope, dyspnea, chest pain, malaise or fatigue accompanied by activity intolerance; documented ECG-documented AF episode that has been unresponsive to conventional therapy (defined as not responding to at least 1 antiarrhythmic drug); left atrium size under 50mm on transthoracic echocardiography determined during eligibility visit;"

Answered by AI

Is this research endeavor still looking for participants?

"According to the data on clinicaltrials.gov, this medical study is recruiting patients in earnest; it was first posted online on November 24th 2021 and recently edited on November 16th 2022."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
CedarsSinaiMC
What portion of applicants met pre-screening criteria?
Met criteria
~9 spots leftby Jun 2025